Five-year budget impact of a prescription digital therapeutic for patients with opioid use disorder

Fulton F. Velez, Danmeng Huang, Lorie Mody, Daniel C. Malone

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Opioid use disorder (OUD) is associated with high healthcare resource utilization (HCRU) and costs. reSET-O is an FDA-cleared prescription digital therapeutic that delivers neurobehavioral therapy as an adjunct to treatment-as-usual (TAU; buprenorphine, face-to-face counseling, and contingency management). Methods: A budget impact model was developed to evaluate reSET-O as an adjunct to TAU in OUD for a 1 million-member US mixed health plan over a 5-year time horizon. Model inputs included treatment costs and medical costs of hospitalizations, partial hospitalizations, intensive care unit stays, and emergency department visits. Results: The base-case results and the alternative scenario analysis showed the addition of reSET-O was projected to result in consistently lower total yearly costs vs TAU and no treatment. The estimated total and per member per month (PMPM) budget impact over 5 years was -$763,026 and -$0.0116, respectively. When the upper range of cost estimates was used, the total and PMPM budget impacts over 5 years were -$2,481,563 and -$0.0378, respectively. Sensitivity analysis showed results were most sensitive to the proportion of patients untreated. Conclusion: The introduction of reSET-O in addition to TAU for OUD has the potential to reduce healthcare resource utilization and costs from 12 weeks up to 5 years.

Original languageEnglish (US)
JournalExpert Review of Pharmacoeconomics and Outcomes Research
DOIs
StateAccepted/In press - 2022
Externally publishedYes

Keywords

  • budget impact
  • buprenorphine
  • cognitive behavioral therapy
  • cost of care
  • digital therapeutic
  • Opioid use disorder
  • OUD
  • PDT
  • prescription digital therapeutic
  • reSET-O

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Five-year budget impact of a prescription digital therapeutic for patients with opioid use disorder'. Together they form a unique fingerprint.

Cite this